Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,074 across all filing types
Latest filing 2024-11-21 Interim / Quarterly Rep…
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vivesto AB for the period 1 January to 30 September 2024. It contains detailed financial statements, management commentary, and operational updates. It is not an announcement of a report, but the report itself, containing substantive financial data and analysis, thus fitting the definition of an Interim/Quarterly Report (IR). 9M 2024
2024-11-21 Swedish
Vivesto signs Apealea option agreement with Zhida Pharmaceutical
M&A Activity Classification · 99% confidence The document is a press release announcing that Vivesto AB has entered into an option agreement with Zhida Pharmaceutical regarding the licensing of the drug Apealea for the Chinese market. It details the terms (milestones, royalties) and next steps (Pre-IND meeting). This type of announcement, which details a significant business transaction (licensing/partnership) but is not a formal regulatory filing like a 10-K or a specific financial report (ER, IR), typically falls under general corporate news. Since the document is a press release announcing a business development, and there is no specific category for 'Business Development Announcement', the most appropriate general category is 'Regulatory Filings' (RNS) as a catch-all for significant, non-standard announcements, or potentially 'Capital/Financing Update' (CAP) if the deal structure was heavily focused on upfront cash, but here it is primarily a licensing deal. Given the options, RNS is the best fit for a general corporate news release about a partnership/licensing agreement that doesn't fit the other specific financial or governance codes. The document length (5969 chars) is substantial enough that it is the report itself, not just an announcement of a report (ruling out RPA).
2024-11-07 English
Vivesto ingår optionsavtal för Apealea med Zhida Pharmaceutical
Regulatory Filings Classification · 100% confidence The document is a press release dated November 7, 2024, announcing that Vivesto AB has entered into an option agreement regarding its cancer product Apealea® with a Chinese pharmaceutical company, Zhida Pharma. This announcement details a potential licensing deal, milestone payments, and future regulatory steps (Pre-IND meeting with NMPA). This type of announcement, detailing a significant business transaction (licensing/partnership) that affects the company's future operations and financial outlook, fits best under Capital/Financing Update (CAP) or potentially Regulatory Filings (RNS) if no other category is suitable. However, since it is a specific announcement about a major business development involving licensing rights and financing terms (milestone payments/royalties), 'CAP' (Capital/Financing Update) is a strong candidate, although 'RNS' (Regulatory Filings) is often used for press releases about material agreements. Given the focus on a major commercial/licensing agreement with financial implications (milestones/royalties), 'CAP' is appropriate, but 'RNS' is the most general fit for non-standardized press releases. Since the definitions do not explicitly cover 'Material Business Agreements' or 'Licensing Deals', and this is a formal announcement of a significant corporate event, I will check the closest fit. 'CAP' covers fundraising/financing activities. This is a licensing deal, which is a form of financing/commercialization agreement. If it were purely a regulatory filing announcement, 'RNS' would apply. Given the financial structure described (milestones/royalties), 'CAP' is plausible. However, looking at the provided list, there is no specific category for 'M&A' or 'Licensing'. The document ends with a statement about being required to be made public under the EU Market Abuse Regulation, suggesting it is a mandatory regulatory disclosure. Therefore, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the safest and most appropriate classification for a press release detailing a material business agreement that doesn't fit the highly specific categories like 10-K, ER, or DIV. The document length (5755 chars) is substantial enough that it is the report itself, not just an announcement of a report, but it is a press release announcing a deal, not a financial report. Thus, RNS is the best fit.
2024-11-07 Swedish
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Vivesto AB for the period of January 1 to June 30, 2024. It contains comprehensive financial statements, including income statements, balance sheet summaries, and detailed management commentary on business operations, R&D progress, and financial performance. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. H1 2024
2024-08-22 Swedish
Report from Annual General Meeting in Vivesto AB
AGM Information Classification · 100% confidence The document is explicitly titled "Report from Annual General Meeting in Vivesto AB" and details the resolutions passed at the meeting held on May 23, 2024, covering the adoption of financial statements, dividend decisions, election of the Board and auditor, and approval of remuneration reports/guidelines. This content directly corresponds to the definition of AGM Information.
2024-05-23 English
Kommuniké från årsstämma i Vivesto AB
AGM Information Classification · 99% confidence The document is titled 'Kommuniké från årsstämma i Vivesto AB' (Communication from the Annual General Meeting in Vivesto AB) and details the decisions made during the meeting held on May 23, 2024. The content covers the approval of financial statements, dividend decisions, election of the board and auditor, approval of remuneration reports, and authorization for future share issues. These topics are central to the proceedings and outcomes of an Annual General Meeting (AGM). Therefore, the appropriate classification is AGM-R (AGM Information). The document length (6047 chars) is substantial enough to be the actual minutes/summary, not just a brief announcement of publication (RPA).
2024-05-23 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.